The FDA has approved the topical Janus kinase inhibitor Opzelura for the treatment of nonsegmental vitiligo in adolescents and adults, Incyte announced in a press release.
Opzelura (ruxolitinib) cream 1.5% is the first FDA-approved treatment for repigmentation in patients with vitiligo.
“This is the start of offering some hope and options to patients who want to be repigmented and hopefully give them the chance to do that,” David Rosmarin, MD, dermatologist and vice chair of research and education for the department of dermatology at Tufts Medical Center and a lead investigator of